Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| So in summary, I'm very proud of our team's execution during the first half of the year |
| And we're really excited for the fourth quarter approaches |
| So I think we've got some benefits with VTX002 that I think are hopefully more attractive attributes to the market |
| As you may have recalled from the R&D discussions in January and from recent press releases, it's been a tremendously productive first half of the year for Ventyx, and I am very proud of our team's execution across the entire pipeline |
| And most of our legacy drugs were about 10% better than placebo |
| And the trajectory is strong to stay on track |
| And I'll just say, from my standpoint, the site activation rates that we had planned were on track, the patient enrollment rates are on track, and I feel confident that we can deliver the results next year |
| In my view, we were quite successful in the ulcerative colitis program with getting the right CRO, the right country mix, the right number of sites, effectively interacting with the investigators and getting the trial enrolled in a timely basis |
| They're continuing to kind of see share coming from all different avenues, which is highly encouraging |
| In conclusion, this is a very exciting period for Ventyx with important top line Phase 2 data for VTX002 and VTX958 just around the corner in the fourth quarter of this year |
| We believe that this approach will create strategic optionality and will unlock the value of these programs in a wide range of indications for future development |
| Our team did an excellent job enrolling this trial in and around six months, with enrollment now complete and we are very excited to report top line data from the Phase 2 SERENITY trial during the fourth quarter |
| And we wouldn't be surprised to see an effect that's at least as good and possibly a little better than what was seen with deucravacitinib and we think that opens up the opportunity for other TYK2 inhibitors with excellent target coverage, like VTX958 |
| They're getting substantial, significant market share relative to the other approved oral therapy on the market in psoriasis |
| We believe we have progress towards achieving the target profile |
| So I think the next generation drugs that would be really differentiated and exciting, you probably want to see at least a 15% and ideally 20% or more placebo adjusted remission rate |
| And I'm grateful for the dedication and perseverance of our team |
| But of course you have the interferon alpha side and that looks good |
| And so we’re really confident in the process |
| But I think we're pleased with the level of screening and enrollment that's going on |
| So in terms of Sotyktu’s commercial performance, I think we're quite encouraged by the early days of Sotyktu |
| And the fact that we have patients enrolled, we're pleased with -- I won't get into the granular details about where we are in that |
| We have seen an overall increase in excitement around the promise of oral therapies, encompassing different targets and indications |
| And I feel confident that we'll be able to have some data late in the year with that program |
| And that was seen both with Sotyktu with the 12 milligram once a day dose in Phase 2 and with the Nimbus-Takeda product at the 30 milligram dose that each of the highest doses and highest exposures had the greatest achievement of PASI 100 |
| On the development of an extended release tablet, ER tablet for VTX958, we continue to make progress towards the target product profile and remain confident that we will have an optimized once daily tablet to advance into Phase 3 trials in 2024 |
| So I think it all looks pretty favorable |
| If you do cross mechanism of action comparisons, those data with the 12 milligram dose actually look pretty favorable to other agents, even JAK inhibitors |
| And our thesis remains that this differentiated pharmacodynamic effect may translate into improved efficacy in ulcerative colitis based on our analysis of consistent observed efficacy driven dose response across both ulcerative colitis and multiple sclerosis trials evaluating S1P1 receptor modulators |
| So I think in terms of where we would like to arrive, really if we get into the zone that the Nimbus-Takeda product achieved, especially where you see the PASI 100 up into the 30s, that's really getting up into a solid area of efficacy from an oral agent |
| Statement |
|---|
| It is no small feat to enroll a large Phase 2 ulcerative colitis trial in a challenging and dynamic environment |
| For lupus, you'll recall that really interleukin 12/23 inhibition with Stelara was ultimately not effective |
| On the S1P class, obviously, Zeposia sales in UC I think has so far underwhelmed versus earlier expectations |
| We've always resisted being too granular about that as we've gone along |
| So what we know is that with deucravacitinib, doses of 6 twice a day or 12 once a day have not been effective for ulcerative colitis and Crohn's disease |
| Firstly, on the QD formulation, I wonder if you could comment on what has been driving the delay here from the midyear update to Q4 and how much more buffer you have to get a QD formulation for Phase 3 studies next year |
| But honestly, we recognize that our earlier timing of data release was probably a little overoptimistic |
Please consider a small donation if you think this website provides you with relevant information